Eli Lilly’s weight-loss pill didn’t work so well, and the stock is tumbling
Lilly’s stock was tumbling as disappointing trial data for an oral weight-loss pill offset an upbeat earnings report and outlook.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
